在細胞治療領域，納米磁珠的突破從未停歇。ACROBiosystems百普賽斯首款實現“全自主技術閉環”的全新一代Cellectra™系列CD4、CD8 T細胞納米分選磁珠正式問世！我們以技術創新為刃，直面行業在材料不對標、穩定性不足、批間差異明顯、臨床轉化困難等核心痛點，經過多維度重復驗證，以扎實數據與嚴苛標準為支撐，以臨床級安全為核心，依托全自主技術閉環與高標準合規體系，為細胞分選提供安全、穩定、高效的一體化解決方案。

為什么選擇Cellectra™系列產品？七大硬核實力給出答案：

ACROBiosystems百普賽斯現重磅推出Cellectra™系列CD4和CD8 T細胞納米分選磁珠：

• 磁珠材質鑒定

Cellectra™ 系列納米磁珠采用醫療級葡聚糖包裹的氧化鐵納米顆粒為原料，具備生物可降解性。磁珠能被抗葡聚糖單克隆抗體（anti-dextran mAb）識別。實驗結果表明，ACROBiosystems百普賽斯與Company M的磁珠均呈抗葡聚糖抗體陽性，而另外兩家商業化磁珠為陰性。由此證明，ACRO納米磁珠生產關鍵原料信息真實可溯、安全特征清晰明確，能夠為客戶藥物的生產與申報工作提供穩定可靠的材料保障。

Human PBMCs (4×107 total cells) were co-isolated using CD4 and CD8 Microbeads (recommended dosage) from Acro and other company products (Company M, Company T, Company G). Post-co-isolation cells from each manufacturer were stained with FITC anti-dextran antibody, PE anti-human CD3 antibody, and 7-AAD, then analyzed by flow cytometry. Notably, no dextran signal from bead-attached cells was detected for Company T or Company G.

Cellectra^TM Human CD4 NanoSort Microbeads

The CD4+ cells were isolated from 1×107human PBMCs using 20μL CellectraTM Human CD4 NanoSort Microbeads, Research grade (Cat. No. MBS-S004) , or other company products (Company M, Company T). The isolated cells and non-isolated cells were respectively stained using FITC anti-human CD4 antibody and 7-AAD, and then analyzed by Flow Cytometry.

Cellectra^TM Human CD8 NanoSort Microbeads

The CD8+ cells were isolated from 1×107 human PBMCs using 20μL CellectraTM Human CD8 NanoSort Microbeads, Research grade (Cat. No. MBS-S005), or other company products (Company M, Company T). The isolated cells and non-isolated cells were respectively stained using PE anti-human CD8 antibody and 7-AAD, and then analyzed by Flow Cytometry.

CD4 NanoSort Microbeads & CD8 NanoSort Microbeads

聯合分選

Human PBMCs (per 107 cells) were isolated 20 μL CD4 NanoSort Microbeads (Cat. No. MBS-S004) and 20 μL CD8 NanoSort Microbeads (Cat. No. MBS-S005), in parallel with other company products (Company M, Company T). Both the isolated cells and non-isolated cells were stained with FITC anti-human CD4 antibody and PE anti-human CD8 antibody (top) and FITC anti-human CD3 antibody (bottom) as well as 7-AAD, and subsequently analyzed using Flow Cytometry.

• 優異的細胞分選性能

Isolation efficacy was validated using samples containing 1×10? human PBMCs processed with the recommended dosage of Cellectra™ Human CD4 NanoSort Microbeads (Fig. A) or Cellectra™ Human CD8 NanoSort Microbeads (Fig. B), in parallel with other company products (Company M, Company T). Comparative analysis demonstrated that Acro NanoSort Microbeads achieved excellent high purity and recovery rates to other company products. Furthermore, high post-isolation cell viability was preserved, confirming suitability for sensitive downstream applications.

• 全方位穩定性驗證

  多供體兼容性、多批次一致性驗證

Minor inter-donor variability was observed in PBMC separation, with high purity and cell recovery consistently maintained (Fig. A). Three batches of CD4 or CD8 NanoSort Microbeads achieved consistent high purity and recovery, confirming robust batch-to-batch consistency and manufacturing reproducibility (Fig. B).

凍融和加速穩定性驗證

Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing (Fig. A). Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use). 

Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles (Fig. B). Following 7 and 14-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.

CD4、CD8納米分選磁珠現開啟試用裝申請活動，掃碼立即參與~